Emily Mercer has been providing strategic consulting services to biopharmaceutical companies since 2017. Prior to joining Blue Matter in 2019, she was a consultant at IQVIA. Emily’s focus areas include rare diseases, medical affairs, and early commercialization. She earned a Ph.D. in Biomedical Sciences from the Weill Cornell Graduate School of Medical Sciences and a B.Sc. in Biochemistry from the University of Surrey.